With in-depth experience in research and clinical development of vaccines in both private and non-private organizations, our executive management team evaluates potential opportunities, develops and implements strategies and guides our technical and scientific staff to achieve Hilleman Laboratories’ mission and goals.
Focused on promoting an innovative health solutions-led science culture and developing a robust pipeline of vaccine research projects, our executive management is responsible for implementing and overseeing the research programmes in an efficient and result oriented manner.
Dr. Davinder Gill
Chief Executive Officer
Dr. Davinder Gill has served as the Chief Executive Officer at Hilleman Laboratories since 2012. Dr. Gill comes with two decades of R&D and business experience in Global Pharma and Biotech companies. At Hilleman Labs, Dr. Gill is responsible for Company Strategy, Product Development, Fund Raising and Public Affairs.
Dr. Gill started his career in 1998 at Millennium Pharmaceuticals in Cambridge, Massachusetts in the area of Biotherapeutics. In 2003, he moved to Wyeth, Collegeville, Pennsylvania where he served in roles of increasing responsibility as Vice President of Biological Technologies. At Wyeth, Dr. Gill was instrumental in creating and leading first-of-their-kind R&D Laboratories in Ireland and Scotland in collaboration with local governments. After the acquisition of Wyeth in 2009, Dr. Gill served as Vice President and Head, Global Biotherapeutics at Pfizer, New York where he successfully led an international team and was a member of Pfizer CEO Council. In 2012, Dr. Gill was appointed CEO at Hilleman Laboratories.
Dr. Gill holds a Ph.D in Chemical Engineering from University of Houston, Texas and is an alumnus of the Indian Institute of Technology. He completed a Cancer Research Institute (New York) Fellowship at the Massachusetts General Hospital/Harvard Medical School in Boston, Massachusetts.
In addition to his role as CEO at Hilleman Labs, Dr. Gill is also a member of The Wellcome Trust (London, UK) Affordable Healthcare Initiative as well as the National Committee on Public Health, Confederation of Indian Industry (New Delhi, India).
Dr. Gill is the founder of a private charity, Amkar Trust.
Mr. Anil Sood
Senior Vice President, Commercial Vaccine Manufacturing
Anil Sood serves as Senior Vice President, Commercial Vaccine Manufacturing at Hilleman Laboratories. Anil brings over 26 years of rich experience in different aspects of Vaccinology like plant commissioning, validation of vaccine manufacturing facilities as per WHO cGMP standards, manufacturing & operations (Vaccine API Manufacturing, Formulation, Fill Finish and Quality Operations). Anil began his career as Technical Supervisor and Technical Officer in Central Research Institute, Kasauli, India. Thereafter, he worked at various positions in Panacea Biotech, serving as Plant Head in his most recent capacity. At Panacea Biotec, Anil was instrumental in various technology transfers, technology assimilations and WHO prequalification of vaccines for UNICEF and PAHO supplies at commercial scales.
Anil has also undertaken teaching and trainings programs for fellows from South East Asian regions, drug regulators and students of microbiology at graduate and post graduate levels in previously served organizations. He serves on the Vaccines Expert Panel of Indian Pharmacopeia and United States Pharmacopeia.
Anil holds a M.Sc. and B.Sc. Degree in Microbiology from Himachal University.
Dr. Ajit Pal Singh
Vice President – Clinical R&D
Dr. Ajit Pal Singh is Vice President – Clinical Research & Development at Hilleman Laboratories. Ajit Pal brings over 18 years of experience in Clinical Development, Regulatory Licensure Strategy and Clinical Trial operations spreading across many countries in Asia, Africa, and South America.
Prior to Hilleman Laboratories, Ajit Pal worked at the International Vaccine Institute based in Seoul, South Korea and at Panacea Biotech based in New Delhi, India. He has successfully undertaken numerous vaccine research projects and obtained WHO Pre-Qualification for 7 vaccines products during this professional tenure. He was also involved in conducting several field studies in collaboration with international organization like Global Polio Eradication Initiative at WHO and icddrb at Dhaka, Bangladesh.
During his career, Ajit Pal has co-authored several publications in peer reviewed journals and has received prestigious Charles C. Shepard Science Award from Centers for Disease Control and Prevention, Atlanta, GA in 2012, which is the preeminent honor recognizing excellence in science for outstanding scientific papers. Ajit Pal was also a planning-group member of ‘Global Vaccine Safety Initiative’ at WHO and an advisor to WHO for Multi-country Collaboration Project on vaccine safety.
Ajit Pal has a MBBS degree from University College of Medical Sciences, New Delhi and has obtained MPH in Public Health & Epidemiology from Chulalongkorn University Thailand.
MS. SWATI YADAV
VICE PRESIDENT – STRATEGIC HRM & BUSINESS SUPPORT
Swati is a Global Human Resource Leader with 18 years of work experience in Strategic HRM.
Swati has worked towards building effective Transformation, Change Management, Leadership and Succession Management. In addition, her work has included Learning & Development, advancing diversity and inclusion initiatives and developing innovative talent management strategies.
Prior to Hilleman Labs, Swati led HR function across Industries and sectors including Pharmaceuticals, Telecommunication, Manufacturing, Consulting and Social Sector in emerging and developed markets in multicultural environment.
Swati is a Post Graduate and Merit Holder in MBA from Xavier Institute of Management, Bhubaneswar. Swati holds graduate degrees in Law and Commerce. Swati is also a certified Career-Life Coach.
Mr. Sourabh Sobti
Vice President – Vaccine Strategy and Implementations
Sourabh Sobti is Vice President -Vaccine Strategy and Implementation at Hilleman Laboratories. Sourabh has over 12 years of experience in consulting, product development and commercialization of vaccines and pharmaceutical products.
Prior to joining Hilleman Labs, Sourabh worked as Senior Manager in Global Markets team at Clinton Health Access Initiative(CHAI) where he managed strategic market access projects at vaccine and pharmaceutical manufacturers in India and South-East Asia to ensure sustainable access to health commodities in low and middle-income countries. Sourabh led due diligence projects for key vaccines, malaria, and oncology products; negotiated pricing agreements to streamline supply and accelerate introduction of quality assured drugs and vaccines.
Prior to CHAI, Sourabh worked as a Management Consultant focusing on Life Sciences sector and was advising pharma and biotech companies on portfolio prioritization, market entry strategy, operating model re-design and business process management projects. Sourabh started his career working as a cell culture process development scientist at UCB and AveciaBiologics in UK.
Sourabh obtained his Masters in Science in Biochemical Engineering from University College London and Bachelors of Sciences (Honors) from Northumbria University at Newcastle UK.